Numinus and MAPS to Collaborate on MDMA Trial for PTSD

Articles

Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding non-profit association dedicated to the study of psychedelics in a first-of-its-kind clinical trial on MDMA.

Numinus has signed a collaboration agreement with the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of MAPS. Together they will seek approval to undertake a single-arm, open-label, compassionate access trial using MDMA-assisted psychotherapy for patients who are suffering from post-traumatic stress disorder (PTSD).

Click here to read more.


UNLOCK INDUSTRY BREAKTHROUGHS, MENTAL HEALTH TIPS, AND MIND ALTERING INSIGHTS.

Stay up to date by subscribing to the Numinus Newsletter.
By signing up you consent to the Privacy Policy & Terms of Use.
Questions?
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram